Geode Capital Management LLC purchased a new position in TuHURA Biosciences (NASDAQ:HURA - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 264,915 shares of the company's stock, valued at approximately $1,084,000. Geode Capital Management LLC owned approximately 0.63% of TuHURA Biosciences at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in the business. Accent Capital Management LLC bought a new stake in TuHURA Biosciences during the fourth quarter worth approximately $29,000. Charles Schwab Investment Management Inc. bought a new stake in shares of TuHURA Biosciences during the 4th quarter worth $61,000. Apollon Wealth Management LLC acquired a new position in shares of TuHURA Biosciences in the 4th quarter worth $253,000. Finally, Suncoast Equity Management acquired a new stake in shares of TuHURA Biosciences during the fourth quarter worth $421,000. Institutional investors own 0.62% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright lowered their price objective on shares of TuHURA Biosciences from $13.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, April 3rd.
Read Our Latest Stock Analysis on HURA
TuHURA Biosciences Price Performance
Shares of NASDAQ HURA traded up $0.02 during mid-day trading on Friday, reaching $3.92. The company had a trading volume of 129,451 shares, compared to its average volume of 258,960. The business has a fifty day simple moving average of $3.35. TuHURA Biosciences has a 12-month low of $1.80 and a 12-month high of $7.93.
About TuHURA Biosciences
(
Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Read More
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
